- The FDA has accepted Exelixis Inc's EXEL supplemental marketing application seeking approval for Cabometyx (cabozantinib) for differentiated thyroid cancer (DTC).
- The application under priority review covers patients 12 years and older who have progressed following prior therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate).
- The agency action date is December 4, 2021.
- Price Action: EXEL shares are down 1.40% at $17.03 during the market session on the last check Thursday.
- Related content: Benzinga's Full FDA Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
